

July 15, 2021
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**Collaborative research with Gunma University to explore
new indications for bendamustine and rigosertib**

TOKYO, Japan, July 15, 2021 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") announced today that it has entered into a joint research agreement with Gunma University to explore new potential indications for bendamustine and rigosertib.

Under the collaboration, SymBio will work with Professor Ken Shirabe, Graduate School of Medicine, Gunma University, and Associate Professor Seshiru Nakazawa, Department of Respiratory Surgery, Center for Surgery, Gunma University Hospital, to seek new potential uses for the compounds, in combination with each other and with other drugs.

By examining the effects associated with inhibiting the linear ubiquitin chain assembly complex (LUBAC), we will investigate the pharmacological effects of the compounds to explore their potential application in solid tumors.

Associate Professor Nakazawa has worked to bridge basic research and clinical applications and has significant research accomplishments in the functional analysis of ubiquitin signals, particularly in the study of the association between LUBAC activation and various diseases.

The Company, utilizing its experience in obtaining approvals for anticancer drugs in shortened timelines, will work with Gunma University to explore new indications for the compounds, to continue to fulfil its mission to address the unmet medical needs of patients.

Statement of Fuminori Yoshida, President and Chief Executive Officer of SymBio: "Based on LUBAC inhibitory effect of bendamustine and the mechanism of action of rigosertib, we will explore new target indications and the development of new therapeutic methods in collaboration with the Graduate School of Medicine of Gunma University."

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

About TREAKISYM®

TREAKISYM® (non-proprietary name: bendamustine hydrochloride), a cytocide anti-cancer drug first used in Germany in the 1970s, is now widely used in more than 50 countries with indications for low-grade non-Hodgkin's lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia.

- TREAKISYM® Intravenous Infusion 100 mg was approved in October 2010 for manufacturing and marketing for the indication of relapsed/refractory low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan.
- TREAKISYM® was approved for the additional indication of chronic lymphocytic leukemia in Japan in August 2016.
- TREAKISYM® was approved for the additional indications of first-line treatment of low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma in Japan in December 2016.
- SymBio achieved the primary endpoint (overall response rate) in Phase 3 study of TREAKISYM® in combination with rituximab as treatment for r/r DLBCL and obtained approval of a partial change application with respect to its marketing approval in March 2021.
- TREAKISYM® ready-to-dilute ("RTD") liquid formulation was approved in Japan in September 2020.
- SymBio aims to achieve annual sales of JPY 10 billion on a NHI drug price basis at the earliest possible stage.

About Rigosertib

Rigosertib is a small molecule inhibitor that has a new mechanism of action: it inhibits the activation of RAS as an oncogene-related product, thereby blocking the action of multikinases, including PI3K, and inhibits cellular signaling in cancer cells necessary for their survival and proliferation, thus killing cancer cells. SymBio obtained the development and commercialization licensing rights for Rigosertib from Onconova in July, 2011 for Japan and Korea.

About Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel drugs to treat cancer, with an initial focus on myelodysplastic syndromes (MDS). Onconova has a pipeline of proprietary targeted agents designed to work against specific cellular pathways that are important in cancer cells. For more information, please visit <https://www.onconova.com>.

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016, SymBio incorporated its wholly-owned subsidiary in the U.S., SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). SymBio's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs.